Beihai Biotech
Latest round
- Series C
Last raised
- Dec 2023
Total raised
- $28M
Investors
- 6
About Beihai Biotech
Established in 2013 and based in Zhuhai, China, Beihai Biotech is a biomedical company that focuses on research and development of anti-tumor drugs. The company has developed 12 authorized invention patents and more than 70 invention patent applications. Besides, it has mastered the technology to improve the solubility of poorly soluble injection drugs. Beihai Biotech won the title of Potential Enterprise in The Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020. In June 2023, the company acquired the Drug Production License. The company's main business is the development of breast cancer, non-small cell cancer, prostate cancer, anti-tumor drugs, and other anticancer drugs. Beihai Biotech owns two drug technology platforms molecular targeted delivery technology platform and PDC technology platform. Its ongoing research projects include BH009, BH002, BH006, etc.
Who invested in Beihai Biotech
6 investors across 4 rounds
See all investors in Beihai Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beihai Biotech
Who invested in Beihai Biotech?
Beihai Biotech has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beihai Biotech raised?
Beihai Biotech has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Beihai Biotech last raise money?
Beihai Biotech's most recent round on record is a Series C, in Dec 2023.
What does Beihai Biotech do?
Established in 2013 and based in Zhuhai, China, Beihai Biotech is a biomedical company that focuses on research and development of anti-tumor drugs.
Where is Beihai Biotech headquartered?
Beihai Biotech is headquartered in Zhuhai, China.
Which VCs invest in companies like Beihai Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Beihai Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Beihai Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.